Kymera Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Net Debt Growth & History (KYMR)
Kymera Therapeutics's net debt was −$274.8M for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$274.8M | −$242.3M | — |
| 2024 | 2024-12-31 | −$32.5M | −$7.2M | — |
| 2023 | 2023-12-31 | −$25.3M | $25.8M | — |
| 2022 | 2022-12-31 | −$51.1M | −$21.0M | — |
| 2021 | 2021-12-31 | −$30.0M | −$17.0M | — |
| 2020 | 2020-12-31 | −$13.0M | $41.8M | — |
| 2019 | 2019-12-31 | −$54.8M | — | — |
Kymera Therapeutics quarterly net debt
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$45.9M | $204.2M | — |
| Q1 2026 | 2026-03-31 | −$63.6M | −$60.0M | — |
| Q4 2025 | 2025-12-31 | −$274.8M | −$242.3M | — |
| Q3 2025 | 2025-09-30 | −$29.0M | −$6.5M | — |
| Q2 2025 | 2025-06-30 | −$250.1M | −$270.7M | — |
| Q1 2025 | 2025-03-31 | −$3.6M | $2.9M | — |
| Q4 2024 | 2024-12-31 | −$32.5M | −$7.2M | — |
| Q3 2024 | 2024-09-30 | −$22.5M | −$22.3M | — |
| Q2 2024 | 2024-06-30 | $20.6M | −$2.1M | −9.29% |
| Q1 2024 | 2024-03-31 | −$6.5M | −$25.1M | — |
| Q4 2023 | 2023-12-31 | −$25.3M | $25.8M | — |
| Q3 2023 | 2023-09-30 | −$208,000 | $138.7M | — |
| Q2 2023 | 2023-06-30 | $22.7M | $82.3M | — |
| Q1 2023 | 2023-03-31 | $18.6M | $34.9M | — |
| Q4 2022 | 2022-12-31 | −$51.1M | −$21.0M | — |
| Q3 2022 | 2022-09-30 | −$138.9M | −$541,000 | — |
| Q2 2022 | 2022-06-30 | −$59.6M | $7.0M | — |
| Q1 2022 | 2022-03-31 | −$16.3M | $19.4M | — |
| Q4 2021 | 2021-12-31 | −$30.0M | −$17.0M | — |
| Q3 2021 | 2021-09-30 | −$138.4M | −$102.3M | — |
| Q2 2021 | 2021-06-30 | −$66.6M | — | — |
| Q1 2021 | 2021-03-31 | −$35.6M | — | — |
| Q4 2020 | 2020-12-31 | −$13.0M | $41.8M | — |
| Q3 2020 | 2020-09-30 | −$36.1M | — | — |
| Q4 2019 | 2019-12-31 | −$54.8M | — | — |
Kymera Therapeutics net debt trends
Over the last five fiscal years, Kymera Therapeutics's net debt decreased from −$13.0M to −$274.8M, a change of −$261.7M. The latest reported quarter, Q2 2026, shows −$45.9M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗